Opzelura is not a steroid. It belongs to a completely different class of medication called Janus kinase (JAK) inhibitors. The active ingredient is ruxolitinib phosphate, and no corticosteroids appear anywhere in its formulation. This distinction matters because Opzelura works through a fundamentally different mechanism than topical steroids and avoids several of the side effects that make long-term steroid use problematic.
How Opzelura Works Instead
Topical steroids broadly suppress inflammation by dialing down the immune system in the area where they’re applied. Opzelura takes a more targeted approach. It blocks two specific enzymes, JAK1 and JAK2, that sit inside skin cells and immune cells. These enzymes act like relay switches: when inflammatory signals (cytokines) arrive at a cell’s surface, JAK1 and JAK2 pass the message along to the cell’s nucleus, telling it to ramp up the immune response. By blocking those switches, Opzelura reduces the inflammatory chain reaction at a precise point in the signaling pathway rather than suppressing the immune system more broadly the way steroids do.
Why the Steroid Question Matters
People searching this question are often concerned about the well-known downsides of topical steroids, especially with long-term use. Those risks include skin thinning (atrophy), stretch marks, visible broken blood vessels, and suppression of the body’s natural cortisol production. Opzelura does not cause these steroid-specific side effects. A VA pharmacy review explicitly noted that it avoids the skin atrophy, stretch marks, broken blood vessels, and hormonal disruption associated with topical corticosteroids.
This is particularly relevant for people dealing with topical steroid withdrawal, a condition where the skin rebounds with intense redness, burning, and flaking after stopping long-term steroid use. There is early clinical evidence that Opzelura can help in these cases. In one published case report, a patient with chronic, treatment-resistant topical steroid withdrawal saw substantial improvement after switching to ruxolitinib cream, with complete resolution of burning and itching at three months. She was able to stop steroids entirely without further flares. The thinking is that JAK inhibitors may calm the rebound inflammatory cascade that drives steroid withdrawal symptoms.
What Opzelura Is Approved to Treat
The FDA has approved Opzelura for two conditions: nonsegmental vitiligo and mild to moderate atopic dermatitis (eczema). For eczema, it’s applied twice daily to affected areas covering up to 20% of the body’s surface. For vitiligo, the same twice-daily application applies but is limited to 10% of body surface area.
In clinical trials for vitiligo, roughly 30% of patients using Opzelura achieved at least 75% repigmentation of their face at 24 weeks, compared to about 7 to 11% of patients using a placebo cream. These results led to its approval as the first FDA-approved treatment specifically for vitiligo repigmentation.
Risks That Are Different From Steroids
While Opzelura avoids steroid-related side effects, it carries its own set of warnings. The FDA requires a boxed warning on the label, the most serious type. This warning covers risks of serious infections, certain cancers (including lymphoma), major cardiovascular events like heart attack and stroke, and blood clots. These risks were primarily identified in studies of oral JAK inhibitors taken at higher doses for rheumatoid arthritis in patients over 50 with existing cardiovascular risk factors. Whether a topical cream applied to small areas of skin carries the same level of risk is still being studied, but the FDA applies the warning to the entire drug class.
You should not use Opzelura if you have an active serious infection. If a serious infection develops during treatment, the prescribing guidance calls for stopping the cream until the infection clears.
Practical Details for Daily Use
Opzelura comes as a cream applied in a thin layer twice a day. There are limits on how much you can use: for adults and children 12 and older, no more than one 60-gram tube per week. For children ages 2 to 11 with eczema, no more than one 60-gram tube every two weeks.
Cost is a significant factor. A single 60-gram tube has a retail price near $2,200. Most insurance plans require prior authorization before covering it, meaning your doctor needs to submit a request explaining why you need it before coverage kicks in. Without that approval, you could be responsible for the full price. The manufacturer does offer a copay savings program that may reduce out-of-pocket costs for eligible patients.
Because of the price and the prior authorization process, many people try topical steroids or other treatments first. Opzelura is often positioned as an option for people who need longer-term treatment or want to avoid the skin-thinning effects that come with extended steroid use, making the “is it a steroid” question one of the most practical distinctions to understand before starting treatment.